Skip to content

Study · Animal study (in vivo) · mouse · 2018

12 results

Intranasal cerebrolysin improves cognitive function and structural synaptic plasticity in photothrombotic mouse model of medial prefrontal cortex ischemia.

Sadigh-Eteghad S, Geranmayeh MH, Majdi A, Salehpour F, Mahmoudi J, Farhoudi M

Neuropeptides10 Jul 2018Cited by 35 (Europe PMC)

PMID30054019 (opens in a new tab)DOI10.1016/j.npep.2018.07.002 (opens in a new tab)PepBankPUB-30054019
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with mPFC ischemia, intraperitoneal Cerebrolysin attenuated episodic memory impairment.

    In plain wordsIn mice with mPFC ischemia, intraperitoneal Cerebrolysin reduced episodic memory impairment.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseEpisodic memory impairment
    Study

    mousen: not reported in source

    Photothrombotic medial prefrontal cortex ischemia
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    2.5 ml/kg · intraperitoneal · two weeksAs given in this study (mouse).

    Source sentences

    Summary
    Treatment with 2.5 ml/kg/i.p. and 1 ml/kg/i.n. doses attenuated mPFC ischemia-induced episodic and spatial memories impairment.
    1 context sentence
    Summary · context
    Thence, CBL (1, 2.5 ml/kg/i.p./daily) or (1 ml/kg/i.n./daily), were administrated in photothrombotic mouse model of mPFC ischemia for two weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with mPFC ischemia, intranasal Cerebrolysin attenuated episodic memory impairment.

    In plain wordsIn mice with mPFC ischemia, intranasal Cerebrolysin reduced episodic memory impairment.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseEpisodic memory impairment
    Study

    mousen: not reported in source

    Photothrombotic medial prefrontal cortex ischemia
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    1 ml/kg · intranasal · two weeksAs given in this study (mouse).

    Source sentences

    Summary
    Treatment with 2.5 ml/kg/i.p. and 1 ml/kg/i.n. doses attenuated mPFC ischemia-induced episodic and spatial memories impairment.
    1 context sentence
    Summary · context
    Thence, CBL (1, 2.5 ml/kg/i.p./daily) or (1 ml/kg/i.n./daily), were administrated in photothrombotic mouse model of mPFC ischemia for two weeks.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with mPFC ischemia, intraperitoneal Cerebrolysin attenuated spatial memory impairment.

    In plain wordsIn mice with mPFC ischemia, intraperitoneal Cerebrolysin reduced spatial memory impairment.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseSpatial memory impairment
    Study

    mousen: not reported in source

    Photothrombotic medial prefrontal cortex ischemia
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    2.5 ml/kg · intraperitoneal · two weeksAs given in this study (mouse).

    Source sentences

    Summary
    Treatment with 2.5 ml/kg/i.p. and 1 ml/kg/i.n. doses attenuated mPFC ischemia-induced episodic and spatial memories impairment.
    1 context sentence
    Summary · context
    Thence, CBL (1, 2.5 ml/kg/i.p./daily) or (1 ml/kg/i.n./daily), were administrated in photothrombotic mouse model of mPFC ischemia for two weeks.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with mPFC ischemia, intranasal Cerebrolysin attenuated spatial memory impairment.

    In plain wordsIn mice with mPFC ischemia, intranasal Cerebrolysin reduced spatial memory impairment.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseSpatial memory impairment
    Study

    mousen: not reported in source

    Photothrombotic medial prefrontal cortex ischemia
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    1 ml/kg · intranasal · two weeksAs given in this study (mouse).

    Source sentences

    Summary
    Treatment with 2.5 ml/kg/i.p. and 1 ml/kg/i.n. doses attenuated mPFC ischemia-induced episodic and spatial memories impairment.
    1 context sentence
    Summary · context
    Thence, CBL (1, 2.5 ml/kg/i.p./daily) or (1 ml/kg/i.n./daily), were administrated in photothrombotic mouse model of mPFC ischemia for two weeks.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice with mPFC ischemia, intraperitoneal Cerebrolysin increased GAP-43 levels in the lesioned area.

    In plain wordsIn mice with mPFC ischemia, intraperitoneal Cerebrolysin increased GAP-43 levels in the damaged area.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseGAP-43 levels
    Study

    mousen: not reported in source

    Photothrombotic medial prefrontal cortex ischemia
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.5 ml/kg · intraperitoneal · two weeksAs given in this study (mouse).

    Source sentences

    Summary
    Results showed an obvious increase in the GAP-43, PSD-95 and SYN levels and improvement in the structural synaptic indexes in lesioned area induced by the same doses and routes of CBL.
    2 context sentences
    Summary · context
    Treatment with 2.5 ml/kg/i.p. and 1 ml/kg/i.n. doses attenuated mPFC ischemia-induced episodic and spatial memories impairment.
    Summary · context
    Thence, CBL (1, 2.5 ml/kg/i.p./daily) or (1 ml/kg/i.n./daily), were administrated in photothrombotic mouse model of mPFC ischemia for two weeks.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice with mPFC ischemia, intranasal Cerebrolysin increased GAP-43 levels in the lesioned area.

    In plain wordsIn mice with mPFC ischemia, intranasal Cerebrolysin increased GAP-43 levels in the damaged area.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseGAP-43 levels
    Study

    mousen: not reported in source

    Photothrombotic medial prefrontal cortex ischemia
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    1 ml/kg · intranasal · two weeksAs given in this study (mouse).

    Source sentences

    Summary
    Results showed an obvious increase in the GAP-43, PSD-95 and SYN levels and improvement in the structural synaptic indexes in lesioned area induced by the same doses and routes of CBL.
    2 context sentences
    Summary · context
    Treatment with 2.5 ml/kg/i.p. and 1 ml/kg/i.n. doses attenuated mPFC ischemia-induced episodic and spatial memories impairment.
    Summary · context
    Thence, CBL (1, 2.5 ml/kg/i.p./daily) or (1 ml/kg/i.n./daily), were administrated in photothrombotic mouse model of mPFC ischemia for two weeks.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In mice with mPFC ischemia, intraperitoneal Cerebrolysin increased PSD-95 levels in the lesioned area.

    In plain wordsIn mice with mPFC ischemia, intraperitoneal Cerebrolysin increased PSD-95 levels in the damaged area.

    Peptide
    Cerebrolysin
    Outcome
    IncreasePSD-95 levels
    Study

    mousen: not reported in source

    Photothrombotic medial prefrontal cortex ischemia
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.5 ml/kg · intraperitoneal · two weeksAs given in this study (mouse).

    Source sentences

    Summary
    Results showed an obvious increase in the GAP-43, PSD-95 and SYN levels and improvement in the structural synaptic indexes in lesioned area induced by the same doses and routes of CBL.
    2 context sentences
    Summary · context
    Treatment with 2.5 ml/kg/i.p. and 1 ml/kg/i.n. doses attenuated mPFC ischemia-induced episodic and spatial memories impairment.
    Summary · context
    Thence, CBL (1, 2.5 ml/kg/i.p./daily) or (1 ml/kg/i.n./daily), were administrated in photothrombotic mouse model of mPFC ischemia for two weeks.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In mice with mPFC ischemia, intranasal Cerebrolysin increased PSD-95 levels in the lesioned area.

    In plain wordsIn mice with mPFC ischemia, intranasal Cerebrolysin increased PSD-95 levels in the damaged area.

    Peptide
    Cerebrolysin
    Outcome
    IncreasePSD-95 levels
    Study

    mousen: not reported in source

    Photothrombotic medial prefrontal cortex ischemia
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    1 ml/kg · intranasal · two weeksAs given in this study (mouse).

    Source sentences

    Summary
    Results showed an obvious increase in the GAP-43, PSD-95 and SYN levels and improvement in the structural synaptic indexes in lesioned area induced by the same doses and routes of CBL.
    2 context sentences
    Summary · context
    Treatment with 2.5 ml/kg/i.p. and 1 ml/kg/i.n. doses attenuated mPFC ischemia-induced episodic and spatial memories impairment.
    Summary · context
    Thence, CBL (1, 2.5 ml/kg/i.p./daily) or (1 ml/kg/i.n./daily), were administrated in photothrombotic mouse model of mPFC ischemia for two weeks.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In mice with mPFC ischemia, intraperitoneal Cerebrolysin increased SYN levels in the lesioned area.

    In plain wordsIn mice with mPFC ischemia, intraperitoneal Cerebrolysin increased SYN levels in the damaged area.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseSYN levels
    Study

    mousen: not reported in source

    Photothrombotic medial prefrontal cortex ischemia
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.5 ml/kg · intraperitoneal · two weeksAs given in this study (mouse).

    Source sentences

    Summary
    Results showed an obvious increase in the GAP-43, PSD-95 and SYN levels and improvement in the structural synaptic indexes in lesioned area induced by the same doses and routes of CBL.
    2 context sentences
    Summary · context
    Treatment with 2.5 ml/kg/i.p. and 1 ml/kg/i.n. doses attenuated mPFC ischemia-induced episodic and spatial memories impairment.
    Summary · context
    Thence, CBL (1, 2.5 ml/kg/i.p./daily) or (1 ml/kg/i.n./daily), were administrated in photothrombotic mouse model of mPFC ischemia for two weeks.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In mice with mPFC ischemia, intranasal Cerebrolysin increased SYN levels in the lesioned area.

    In plain wordsIn mice with mPFC ischemia, intranasal Cerebrolysin increased SYN levels in the damaged area.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseSYN levels
    Study

    mousen: not reported in source

    Photothrombotic medial prefrontal cortex ischemia
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    1 ml/kg · intranasal · two weeksAs given in this study (mouse).

    Source sentences

    Summary
    Results showed an obvious increase in the GAP-43, PSD-95 and SYN levels and improvement in the structural synaptic indexes in lesioned area induced by the same doses and routes of CBL.
    2 context sentences
    Summary · context
    Treatment with 2.5 ml/kg/i.p. and 1 ml/kg/i.n. doses attenuated mPFC ischemia-induced episodic and spatial memories impairment.
    Summary · context
    Thence, CBL (1, 2.5 ml/kg/i.p./daily) or (1 ml/kg/i.n./daily), were administrated in photothrombotic mouse model of mPFC ischemia for two weeks.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In mice with mPFC ischemia, intraperitoneal Cerebrolysin improved structural synaptic indexes.

    In plain wordsIn mice with mPFC ischemia, intraperitoneal Cerebrolysin improved structural synaptic measures.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedStructural synaptic indexes
    Study

    mousen: not reported in source

    Photothrombotic medial prefrontal cortex ischemia
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    2.5 ml/kg · intraperitoneal · two weeksAs given in this study (mouse).

    Source sentences

    Summary
    Results showed an obvious increase in the GAP-43, PSD-95 and SYN levels and improvement in the structural synaptic indexes in lesioned area induced by the same doses and routes of CBL.
    2 context sentences
    Summary · context
    Treatment with 2.5 ml/kg/i.p. and 1 ml/kg/i.n. doses attenuated mPFC ischemia-induced episodic and spatial memories impairment.
    Summary · context
    Thence, CBL (1, 2.5 ml/kg/i.p./daily) or (1 ml/kg/i.n./daily), were administrated in photothrombotic mouse model of mPFC ischemia for two weeks.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In mice with mPFC ischemia, intranasal Cerebrolysin improved structural synaptic indexes.

    In plain wordsIn mice with mPFC ischemia, intranasal Cerebrolysin improved structural synaptic measures.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedStructural synaptic indexes
    Study

    mousen: not reported in source

    Photothrombotic medial prefrontal cortex ischemia
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    1 ml/kg · intranasal · two weeksAs given in this study (mouse).

    Source sentences

    Summary
    Results showed an obvious increase in the GAP-43, PSD-95 and SYN levels and improvement in the structural synaptic indexes in lesioned area induced by the same doses and routes of CBL.
    2 context sentences
    Summary · context
    Treatment with 2.5 ml/kg/i.p. and 1 ml/kg/i.n. doses attenuated mPFC ischemia-induced episodic and spatial memories impairment.
    Summary · context
    Thence, CBL (1, 2.5 ml/kg/i.p./daily) or (1 ml/kg/i.n./daily), were administrated in photothrombotic mouse model of mPFC ischemia for two weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.